share_log

Avant and IMC Execute BLK MKT Trademark Licensing Agreement for the German Medical Cannabis Market

Avant and IMC Execute BLK MKT Trademark Licensing Agreement for the German Medical Cannabis Market

Avant 和 IMC 爲德國醫用大麻市場執行 BLK MKT 商標許可協議
PR Newswire ·  04/04 07:30

TORONTO, GLIL YAM, Israel and KELOWNA, BC., April 4, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, and Avant Brands Inc. (TSX: AVNT) (OTCQX: AVTBF) (FRA: 1BU0) ("Avant") a leading producer of innovative cannabis products, jointly announce the signing of an international trademark licensing agreement (the "Licensing Agreement") granting Adjupharm GmbH, IMC's German subsidiary ("Adjupharm" or "IMC Germany", as applicable), the exclusive right to launch the BLK MKT brand in the German medical cannabis market. The Licensing Agreement constitutes another major milestone with respect to the relationship between the two cannabis companies.

多倫多,GLIL YAM,以色列和不列顛哥倫比亞省基洛納,2024 年 4 月 4 日 /PRNewswire/ — IM Cannabis Corp.(CSE:IMCC)(納斯達克股票代碼:IMCC)(the”公司“,”我大麻“,或”IMC“),一家在以色列和德國開展業務的領先醫用大麻公司,以及Avant Brands Inc.(多倫多證券交易所股票代碼:AVNT)(OTCQX:AVTBF)(FRA:1BU0)(”前衛“)領先的創新大麻產品生產商,共同宣佈簽署國際商標許可協議(”許可協議“) 授予 IMC 的德國子公司 Adjupharm GmbH(”Adjupharm“或”IMC 德國“,視情況而定),推出 BLK MKT 的專有權利 德國醫用大麻市場的品牌。許可協議是兩家大麻公司之間關係的又一個重要里程碑。

Under the terms of the Trademark License Agreement, Avant's subsidiary will grant IMC Germany the license to utilize Avant's BLK MKTTM cannabis brand for use on their medical cannabis products. All such products will contain cannabis cultivated exclusively by Avant and subsequently exported to Germany. The collaboration between the two companies anticipates a positive outcome in the emerging German medical cannabis market, especially following the recent legalization by the government on April 1st.

根據商標許可協議的條款,Avant的子公司將授予德國IMC使用Avant的BLK MKT的許可TM 用於其醫用大麻產品的大麻品牌。所有這些產品都將包含由Avant專門種植並隨後出口到德國的大麻。兩家公司之間的合作預計德國新興醫用大麻市場將取得積極成果,尤其是在政府最近於4月1日合法化之後st

The Licensing Agreement signals IMC's commitment to implementing a premium strategy in Germany as well as in Israel and acts as another step to establish Avant's position in the ultra-premium segment in Israel and Germany. IMC and Avant have had a productive partnership so far, combining Avant's premium cannabis products with IMC's sales, marketing and distribution expertise in Israel. Both companies believe the Licensing Agreement will enhance the companies' capabilities to meet the demands of the German market.

該許可協議表明了IMC承諾在德國和以色列實施溢價戰略,也是確立Avant在以色列和德國超高端細分市場地位的又一步。到目前爲止,IMC和Avant建立了富有成效的合作伙伴關係,將Avant的優質大麻產品與IMC在以色列的銷售、營銷和分銷專業知識相結合。兩家公司都認爲,許可協議將增強兩家公司滿足德國市場需求的能力。

"By evolving our partnership with Avant, we continue to improve our supply chain and ability to provide ultra-premium, quality brand and product to the German medical cannabis market," Oren Shuster, CEO of IMC commented.

“通過發展與Avant的合作伙伴關係,我們將繼續改善我們的供應鏈和向德國醫用大麻市場提供超優質、優質的品牌和產品的能力,” 奧倫·舒斯特,IMC首席執行官評論道。

"We believe that our collaboration with Avant will continue to accelerate the strong momentum we have established in the German medical cannabis market," stated Richard Balla, CEO of IMC Germany.

他說:“我們相信,我們與Avant的合作將繼續加速我們在德國醫用大麻市場建立的強勁勢頭。” 理查德·巴拉, 德國IMC首席執行官。

"This agreement represents another major milestone with respect to our highly successful multi-year partnership with IMC," said Norton Singhavon, CEO, Avant Brands.

他說:“該協議是我們與IMC非常成功的多年合作伙伴關係的又一個重要里程碑。” 諾頓·辛哈文,Avant Brands首席執行官。

"We are very excited to be working with IMC's German team" said David Lynn, COO, Avant Brands. "We are confident that they will do an outstanding job launching the BLK MKT brand in Germany".

他說:“我們很高興能與IMC的德國團隊合作。” 大衛·林恩,Avant Brands 首席運營官。“我們相信,他們將在德國推出BLK MKT品牌方面做得非常出色”。

Avant's three largest cultivation facilities all hold ICANN-GAP and GACP certifications; thus, Avant is positioned to potentially distribute its premium cannabis flower into international markets.

Avant最大的三個種植設施均擁有ICANN-GAP和GACP認證;因此,Avant有望將其優質大麻花分銷到國際市場。

IMC Germany is the 6th largest distributor of medical cannabis flowers in Germany and is number 1 in sales per SKU, growing +180% in 2023.1

IMC Germany 是 6第四 德國最大的醫用大麻花分銷商,每個SKU的銷售額排名第一,2023年增長了180%。1

1Insight Health December 2023

1洞察健康 2023 年 12 月

About IM Cannabis Corp.

關於 IM Cannabis

IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has recently exited operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

IMC(納斯達克股票代碼:IMCC)(CSE:IMCC)是一家國際大麻公司,爲最大的兩個醫用大麻市場以色列和德國的醫療患者提供優質大麻產品。該公司最近退出了在加拿大的業務,將重點和資源轉移到其最高價值的市場以色列和德國實現可持續和盈利的增長。該公司利用由獨特的數據驅動方法和全球來源的產品供應鏈提供支持的跨國生態系統。公司堅定不移地致力於負責任的增長並遵守最嚴格的監管環境,努力擴大其商業和品牌力量,成爲全球高質量的大麻生產商。

The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Until recently, the Company also actively operated in Canada through Trichome Financial Corp and its wholly owned subsidiaries, where it cultivated, processed, packaged, and sold premium and ultra-premium cannabis for the adult-use market in Canada. The Company has exited operations in Canada and considers these operations discontinued.

IMC生態系統通過與Focus Medical Herbs Ltd.的商業關係在以色列運營。Focus Medical Herbs Ltd.利用多年的專有數據和患者見解向醫療患者進口和分銷大麻。該公司還在以色列經營醫用大麻零售藥房、在線平台、配送中心和物流中心,從而實現整個價值鏈中IMC產品的安全交付和質量控制。在德國,IMC生態系統通過Adjupharm GmbH運營,向藥房分發大麻供醫用大麻患者使用。直到最近,該公司還通過Trichome Financial Corp及其全資子公司在加拿大積極開展業務,爲加拿大成人用途市場種植、加工、包裝和銷售優質和超優質大麻。該公司已退出在加拿大的業務,並認爲這些業務已終止。

Disclaimer for Forward-Looking Statements

前瞻性陳述的免責聲明

This press release contains forward-looking information or forward-looking statements under applicable Canadian and U.S. securities laws (collectively, "forward-looking statements"). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "likely" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to statements relating to compliance with Nasdaq's continued listing requirements, and timing and effect thereof and the potential for an extension to regain compliance; Company leaving the Canadian cannabis market to focus on Israel, Germany and Europe and the potential outcome of the Licensing Agreement and the effect of collaboration with Avant in the German market.

本新聞稿包含適用的加拿大和美國證券法規定的前瞻性信息或前瞻性陳述(統稱爲 “前瞻性陳述”)。涉及我們預計將來發生的活動或發展的所有信息均爲前瞻性陳述。前瞻性陳述通常使用 “尋求”、“預測”、“相信”、“計劃”、“估計”、“預期”、“可能” 和 “打算” 等詞語來識別,以及關於某一事件或結果 “可能”、“將”、“應該”、“可能” 或 “可能” 發生或實現的陳述以及其他類似的表述。前瞻性陳述基於管理層在陳述發表之日的估計和意見。在新聞稿中,此類前瞻性陳述包括但不限於與遵守納斯達克持續上市要求有關的陳述、其時機和影響,以及延期以恢復合規的可能性;公司離開加拿大大麻市場專注於以色列、德國和歐洲,以及許可協議的潛在結果以及與Avant合作在德國市場的影響。

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company's ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus Medical (collectively, the "Group") to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group's obligations; the Group's possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group's cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt and war, conflict and civil unrest in Eastern Europe and the Middle East.

上述前瞻性陳述和假設清單並不詳盡。由於前瞻性陳述涉及未來的事件和狀況,因此就其本質而言,它們涉及固有的風險和不確定性。由於多種因素和風險,實際結果可能與此類前瞻性陳述目前的預期或暗示的結果存在重大差異。其中包括:公司未能遵守監管嚴格的行業中適用的監管要求;公司運營所在司法管轄區的政府政策和法規的意外變化;公司繼續滿足加拿大證券交易所和納斯達克資本市場的上市要求的能力;任何意外未能保持良好信譽或續訂其執照;公司和Focus Medical(統稱爲 “集團”)兌現其銷售承諾或增長的能力目標;集團依賴第三方供應協議提供足夠數量的醫用大麻以履行集團的義務;集團可能承擔的責任風險、與之相關的風險水平以及涉及集團的任何訴訟或其他類似爭議或法律訴訟的預期結果;競爭加劇的影響;缺乏併購機會;不利的市場條件;產量、質量和成本估算的固有不確定性以及潛在的意外成本和支出;使用集團大麻產品造成的產品責任和其他安全相關責任風險;供應鏈限制;對關鍵人員的依賴;拖欠現有債務的風險以及東歐和中東的戰爭、衝突和內亂。

Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

本新聞稿中包含的任何前瞻性陳述均自本新聞稿發佈之日起作出,並基於管理層在發佈此類前瞻性信息之日的信念、估計、預期和觀點。除非適用的證券法要求,否則公司不承擔任何更新前瞻性陳述的義務。投資者不應過分依賴前瞻性陳述。本警示聲明明確限制了本新聞稿中包含的前瞻性陳述。

Company Contact:

公司聯繫人:

Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]

安娜·塔蘭科,投資者與公共關係總監
IM 大麻公司
+49 157 80554338
[電子郵件保護]

Oren Shuster, CEO
IM Cannabis Corp.
[email protected]

首席執行官奧倫·舒斯特
IM 大麻公司
[電子郵件保護]

Logo -

徽標-

SOURCE IM Cannabis Corp.

來源 IM Cannabis公司

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論